Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1990 1
1992 1
1994 1
1995 2
1998 1
1999 1
2001 1
2003 1
2005 1
2007 1
2009 2
2011 1
2012 2
2013 2
2014 3
2015 1
2016 8
2017 7
2018 3
2019 1
2020 2
2021 3
2022 2
2023 5
2024 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

52 results

Results by year

Filters applied: . Clear all
Page 1
A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease.
Schuppan D, Mäki M, Lundin KEA, Isola J, Friesing-Sosnik T, Taavela J, Popp A, Koskenpato J, Langhorst J, Hovde Ø, Lähdeaho ML, Fusco S, Schumann M, Török HP, Kupcinskas J, Zopf Y, Lohse AW, Scheinin M, Kull K, Biedermann L, Byrnes V, Stallmach A, Jahnsen J, Zeitz J, Mohrbacher R, Greinwald R; CEC-3 Trial Group. Schuppan D, et al. Among authors: hovde o. N Engl J Med. 2021 Jul 1;385(1):35-45. doi: 10.1056/NEJMoa2032441. N Engl J Med. 2021. PMID: 34192430 Free article. Clinical Trial.
Transcriptomic analysis of intestine following administration of a transglutaminase 2 inhibitor to prevent gluten-induced intestinal damage in celiac disease.
Dotsenko V, Tewes B, Hils M, Pasternack R, Isola J, Taavela J, Popp A, Sarin J, Huhtala H, Hiltunen P, Zimmermann T, Mohrbacher R, Greinwald R, Lundin KEA, Schuppan D, Mäki M, Viiri K; CEC-3 Investigators. Dotsenko V, et al. Nat Immunol. 2024 Jul;25(7):1218-1230. doi: 10.1038/s41590-024-01867-0. Epub 2024 Jun 24. Nat Immunol. 2024. PMID: 38914866 Free PMC article. Clinical Trial.
Clinical course of ulcerative colitis: Frequent use of biologics and low colectomy rate first year after diagnosis-results from the IBSEN III inception cohort.
Strande V, Lund C, Hagen M, Bengtson MB, Cetinkaya RB, Detlie TE, Frigstad SO, Høie O, Medhus AW, Henriksen M, Aass Holten KI, Hovde Ø, Huppertz-Hauss G, Johansen I, Olsen BC, Opheim R, Ricanek P, Torp R, Tønnessen T, Vatn S, Aabrekk TB, Høivik ML, Kristensen VA. Strande V, et al. Among authors: hovde o. Aliment Pharmacol Ther. 2024 Aug;60(3):357-368. doi: 10.1111/apt.18097. Epub 2024 Jun 4. Aliment Pharmacol Ther. 2024. PMID: 38837289
Dietary intake and nutritional status in patients with newly diagnosed inflammatory bowel disease: insights from the IBSEN III study.
Zerouga I, Valeur J, Sommer C, Cvancarova Småstuen M, Medhus AW, Lund C, Johansen I, Cetinkaya RB, Bengtson MB, Torp R, Hovde Ø, Huppertz-Hauss G, Detlie TE, Aabrekk TB, Ricanek P, Frigstad SO, Hopstock LA, Opheim R, Kristensen VA, Høivik ML, Hauger Carlsen M, Aas AM. Zerouga I, et al. Among authors: hovde o. Scand J Gastroenterol. 2024 Jun;59(6):652-660. doi: 10.1080/00365521.2024.2313056. Epub 2024 Feb 15. Scand J Gastroenterol. 2024. PMID: 38356408
Fatigue in Patients with Newly Diagnosed Inflammatory Bowel Disease: Results from a Prospective Inception Cohort, the IBSEN III Study.
Holten KIA, Bernklev T, Opheim R, Johansen I, Olsen BC, Lund C, Strande V, Medhus AW, Perminow G, Bengtson MB, Cetinkaya RB, Vatn S, Frigstad SO, Aabrekk TB, Detlie TE, Hovde Ø, Kristensen VA, Småstuen MC, Henriksen M, Huppertz-Hauss G, Høivik ML, Jelsness-Jørgensen LP. Holten KIA, et al. Among authors: hovde o. J Crohns Colitis. 2023 Nov 24;17(11):1781-1790. doi: 10.1093/ecco-jcc/jjad094. J Crohns Colitis. 2023. PMID: 37279652 Free PMC article.
52 results